SEC Comment Letter for TELA Bio, (TELA) — Dec 23, 2020
TELA Bio, Inc.
Date: Dec. 23, 2020 · CIK: 0001561921 · Accession: 0000000000-20-012367
AI Filing Summary & Sentiment
File numbers found in text: 333-251505
Letter
United States securities and exchange commission logo December 23, 2020 Nora Brennan Chief Financial Officer TELA Bio, Inc. 1 Great Valley Parkway, Suite 24 Malvern, Pennsylvania 19355 Re:TELA Bio, Inc. Registration Statement on Form S-3 Filed December 18, 2020 File No. 333-251505 Dear Ms. Brennan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Laura Crotty at 202-551-7614 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rachael Bushey
Show Raw Text
United States securities and exchange commission logo
December 23, 2020
Nora Brennan
Chief Financial Officer
TELA Bio, Inc.
1 Great Valley Parkway, Suite 24
Malvern, Pennsylvania 19355
Re:TELA Bio, Inc.
Registration Statement on Form S-3
Filed December 18, 2020
File No. 333-251505
Dear Ms. Brennan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Laura Crotty at 202-551-7614 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Rachael Bushey